Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print RSS Feed

Expert's Opinion

Gurpreet Sandhu, Reva Pharmaceuticals
June 18, 2014
Biosimilars face far more demanding clinical, market access, manufacturing and sales and marketing requirements, than small-molecule generics did.  Read More »
Fereshteh Barei, Dauphine University
June 18, 2014
Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing   Read More »
Girish Malhotra, President, EPCOT International
April 9, 2014
Will Sun’s latest acquisition, and India's first peer-to-peer pharma mega-buy, change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?  Read More »
Emil Ciurczak, Consultant, DoraMaxx Consulting
April 9, 2014
Pharmaceutical operations, of all kinds, are simply too complex to rely on univariate thinking  Read More »
Andrew Badrot, CMS Pharma
January 30, 2014
DSM & Patheon unlock value through a creative merger  Read More »
David Shoemaker, Ph.D., Senior Vice President, R&D, Rho
January 8, 2014
Policy precedes science  Read More »
Ken Phelps, President and CEO, Camargo Pharmaceutical Services
November 6, 2013
505(b)(2) can result in product approval with lower risk, reduced costs, and faster time to market  Read More »
Jeff Wilson and Dave Kerns, Key Corporate Services, LLC
August 2, 2013
Behavioral interviewing to match job and job-seeker  Read More »
Mike Rozembajgier, vice president of Recalls, Stericycle ExpertRECALL
June 3, 2013
Recall simulations prepare pharma companies for the real deal  Read More »
Jeffery R. Nelson, CEO, Nelson Laboratories
July 13, 2012
NRCM can increase knowledge and confidence and become part of the culture  Read More »
Edward S. Price, PCI Synthesis
July 10, 2012
What to look for, and why  Read More »
Edward S. Price, PCI Synthesis
May 30, 2012
Big Pharma and venture capital reshape the CMO/CRO markets  Read More »
Andrew Badrot
May 15, 2012
What does the Kensey Nash deal say about DSM's growth strategy?  Read More »
Andreas Scherer, Ph.D.
March 21, 2012
Holy Grail or Buying Time?  Read More »
Tim Clark
February 29, 2012
An initial take on the Agency's proposal for biosimilars  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On